News

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

Hub signal

Search-friendly coverage

Keep the current route structure, but present it with the same premium hierarchy as the homepage.

Explore

Search-friendly hub pages

Regulators

Regulatory Updates

FDA, EMA, PMDA, MHRA, and global regulatory coverage in one crawlable hub.

Open hub

Trials

Clinical Trial Watch

Phase readouts, trial design updates, enrollment milestones, and study results.

Open hub

Pipeline

Drug Pipeline

Regulatory pipeline signals, approvals, and market-moving development updates.

Open hub

Live pharma index

Full coverage

Every signal, indexed and searchable

Browse the complete catalog across approvals, trials, research, devices, and deals - refreshed twice a day.

350+

trusted sources

8k+

indexed stories

daily refresh

Coverage

Latest indexed stories

8,238 stories indexed, page 27 of 138

🇨🇭Jun 1CROpsi-cro.com

Featured signal

Fast-tracking enrollment in personalized immunotherapy for melanoma

Publisher

PSI CRO

Limited excerpt on-platform. Click anywhere on this card to open the original publisher in a new tab.

PSI CROOriginal publisher link

Canonical metadata stays public, while full text remains on the original site.

🇬🇧Jun 1Researched.ac.uk

Women’s health at heart of new Edinburgh pop-up festival

University of EdinburghOriginal source

🇪🇸Jun 1Researchcnio.es

Guadalupe Sabio wins a Diario Médico’s Admirables Award

CNIO (Spain Cancer News)Original source

🇺🇸Jun 1Researchnews.nm.org

After a tumor disrupts an Illinois woman’s fertility, brain surgery helps her get pregnant

Northwestern MedicineOriginal source

🇫🇷Jun 1Researchchru-strasbourg.fr

Journée mondiale sans tabac : les HUS engagés dans le soin et la prévention

Hôpitaux Universitaires de StrasbourgOriginal source

🇬🇧Jun 1Researchukri.org

Public dialogue explores solar radiation modification research

Medical Research Council (UKRI)Original source

🇩🇪Jun 1Mediacharite.de

Mit Bakterien zu klimaneutralen Kunststoffen und Kosmetika

Charité - Universitätsmedizin Berlin (EN)Original source

🇩🇪Jun 1Researchcharite.de

Making climate-neutral plastics and cosmetics using bacteria

Charité - Universitätsmedizin Berlin (EN)Original source

🌍Jun 1Industryhealth.ucdavis.edu

From the Emergency Department to the Capitol: A doctor’s impact beyond the bedside

UC Davis HealthOriginal source

🌍Jun 1Industryhealth.ucdavis.edu

Survey shows little shift in Americans’ views on political violence

UC Davis HealthOriginal source

🇮🇹Jun 1Researchpoliclinico.mi.it

Il Policlinico di Milano vanta una delle biblioteche ospedaliere più importanti d’Europa

Policlinico di MilanoOriginal source

🌍Jun 1Industryavacta.com

Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026

Avacta GroupOriginal source

🇫🇷Jun 1Researchinserm.fr

Comment diminuer le nombre de maladies cardiovasculaires ?

InsermOriginal source

🌍Jun 1Medianovartis.com

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

NovartisOriginal source

🇨🇭Jun 1Industryroche.com

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche NewsroomOriginal source

🇨🇭Jun 1CDMOsiegfried.ch

Change in Siegfried’s management team

SiegfriedOriginal source

🌍Jun 1Researchpnas.org

Cyclic deformation resets a rock’s microstructural clock

PNASOriginal source

🇯🇵Jun 1Regulatorypmda.go.jp

[IBENTO][IBENTO]Symposium for the 10 anniversary of the PMDA Hokuriku Branch

PMDA JapanOriginal source

🇯🇵Jun 1Industrysumitomo-pharma.com

Sumitomo Pharma Announces Organizational Change, Change in the Responsibilities of Executive Officer, and Personnel Change

Sumitomo PharmaOriginal source

🌍Jun 1Industrymenicon.com

Flat Pack Packaging Now Uses Less Plastic with New Direct Printing Machine

MeniconOriginal source

🇬🇧Jun 1Researchthelancet.com

[Editorial] The promise and perils of AI in oncology

Lancet OncologyOriginal source

🇬🇧Jun 1Researchthelancet.com

[Correspondence] Para-aortic lymph nodes in oligometastatic pancreatic ductal adenocarcinoma – Authors' reply

Lancet OncologyOriginal source

🇬🇧Jun 1Researchthelancet.com

[Correspondence] On the survival benefit from sentinel node biopsy for melanoma – Authors' reply

Lancet OncologyOriginal source

🇬🇧Jun 1Researchthelancet.com

[Corrections] Correction to Lancet Oncol 2026; 27: e238–47

Lancet OncologyOriginal source

🇬🇧Jun 1Researchthelancet.com

[Corrections] Correction to Lancet Oncol 2026; 27: 614–24

Lancet OncologyOriginal source

🇬🇧Jun 1Researchthelancet.com

[Comment] [177Lu]Lu-dota-tate radioligand therapy for advanced pancreatic neuroendocrine tumours

Lancet OncologyOriginal source

🇬🇧Jun 1Researchthelancet.com

[Correspondence] Para-aortic lymph nodes in oligometastatic pancreatic ductal adenocarcinoma

Lancet OncologyOriginal source

🇬🇧Jun 1Researchthelancet.com

[Correspondence] On the survival benefit from sentinel node biopsy for melanoma

Lancet OncologyOriginal source

🇬🇧Jun 1Researchthelancet.com

[Correspondence] Brachytherapy capacity gaps and cancer control priorities

Lancet OncologyOriginal source

🇯🇵Jun 1Industrysanten.com

当社名をかたるSNSなりすましアカウントに関する注意喚起

Santen Pharmaceutical NewsOriginal source

🇯🇵Jun 1Industrysanten.com

「健康経営優良法人2026（大規模法人部門）」に認定

Santen Pharmaceutical NewsOriginal source

🇯🇵Jun 1Industrysanten.com

S&P GlobalによるSustainability Yearbook Member 2026に選定

Santen Pharmaceutical NewsOriginal source

🇯🇵Jun 1Industrysanten.com

緑内障・高眼圧症治療剤「ロープレッサ®点眼液0.02%」国内における製造販売承認を取得

Santen Pharmaceutical NewsOriginal source

🇯🇵Jun 1Industrysanten.com

「ちびまる子ちゃん」と考える、子どもの近視 ― 日常の気づきから“まずは眼科へ”を伝える疾患啓発メッセージを全国に展開 ―

Santen Pharmaceutical NewsOriginal source

🇯🇵Jun 1Industrysanten.com

Santen中国、5つの緑内障点眼薬について、中国本土における独占的な流通および販売促進に関する契約を締結

Santen Pharmaceutical NewsOriginal source

🇯🇵Jun 1Industrysanten.com

後天性眼瞼下垂治療剤「アップニーク®ミニ点眼液0.1%」発売のお知らせ

Santen Pharmaceutical NewsOriginal source

🇯🇵Jun 1Industrysanten.com

役員人事に関するお知らせ

Santen Pharmaceutical NewsOriginal source

🇯🇵Jun 1Industrysanten.com

＜花粉症に対する意識調査＞花粉症で「パフォーマンスに影響あり」は8割以上「初期療法（早期治療）」を正しく知っている人の半数以上は「毎年実施」～眼科医と気象予報士が解説、花粉飛散期前の対策で春をより快適に～

Santen Pharmaceutical NewsOriginal source

🇯🇵Jun 1Industrysanten.com

アフリベルセプト硝子体内注射用キット40 mg/mL「バイエル」の発売予定について

Santen Pharmaceutical NewsOriginal source

🇬🇧Jun 1Researchnature.com

AAV8-mediated mouse/human PROC expression rescues thrombophilia in hereditary protein C-deficient mice

Nature Gene TherapyOriginal source

🇩🇪Jun 1Researchfraunhofer.de

Efficient Bridge Monitoring

Fraunhofer Life SciencesOriginal source

🇩🇪Jun 1Researchfraunhofer.de

Accelerating the Production of Higher-Performance Batteries

Fraunhofer Life SciencesOriginal source

🇺🇸Jun 1Researchonlinejcf.com

Outcomes of DCD Versus DBD Heart Transplantation: Impact of Primary Graft Dysfunction Recovery Trajectory

Journal of Cardiac FailureOriginal source

🇯🇵Jun 1Industrykifu-shinsei.jp

2026年度「参天製薬奨学寄付プログラム」の応募を開始いたしました

Santen Pharmaceutical NewsOriginal source

🌍May 31Industryeikontx.com

Efficacy, safety and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to Standard of Care First-Line Therapy: the Phase 2 TeLuRide-005 trial in Stage 4 Non-Small Cell Lung Cancer – Poster Presentation, ASCO 2026

Eikon TherapeuticsOriginal source

🌍May 31Industryeikontx.com

Adaptive Phase 2/3 Study of EIK1001, a TLR7/8 Dual Agonist, in Combination with Pembrolizumab, as First-Line Therapy in Participants with Advanced Melanoma (TeLuRide-006) – Poster Presentation, ASCO 2026

Eikon TherapeuticsOriginal source

🌍May 31Industryeikontx.com

A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008) – Poster Presentation, ASCO 2026

Eikon TherapeuticsOriginal source

🇺🇸May 31Industryinvestor.lilly.com

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

Eli Lilly NewsOriginal source

🇬🇧May 31Researchthelancet.com

[Comment] From shortage to synergy: transforming global radiology workforce capacity with digital innovation and task-shifting

Lancet OncologyOriginal source

🇬🇧May 31Researchthelancet.com

[Comment] Regionally anchored, globally connected: lessons from the Pacific on the cancer workforce crisis

Lancet OncologyOriginal source

🇬🇧May 31Researchthelancet.com

[Comment] The global cancer workforce crisis: a shared responsibility, a united front

Lancet OncologyOriginal source

🇬🇧May 31Researchthelancet.com

[Comment] Beyond the count: the unseen foundations of cancer care

Lancet OncologyOriginal source

🇬🇧May 31Researchthelancet.com

[Comment] AI and the cancer workforce: what problem are we solving?

Lancet OncologyOriginal source

🇬🇧May 31Researchthelancet.com

[Comment] The UK's radiotherapy workforce shortage: a case for reform

Lancet OncologyOriginal source

🌍May 31Industrymonashhealth.org

Taking cooking together to the next level: an inspiring story from Community Kids Narre Warren

Monash HealthOriginal source

🌍May 31Medianovartis.com

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

NovartisOriginal source

🌍May 31Industryeikontx.com

A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, Including Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors – Poster Presentation, ASCO 2026

Eikon TherapeuticsOriginal source

🌍May 31Industryeikontx.com

EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a Phase 1/2 study EIK1003-001 in advanced solid tumors – Poster Presentation, ASCO 2026

Eikon TherapeuticsOriginal source

🌍May 31Industryeikontx.com

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Eikon TherapeuticsOriginal source

🇺🇸May 31Industrybristolmyers2016ir.q4web.com

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

Bristol-Myers Squibb NewsOriginal source

Pharmaceutical industry news

Search-friendly hub pages

Regulatory Updates

Clinical Trial Watch

Drug Pipeline

Every signal, indexed and searchable

Latest indexed stories

Fast-tracking enrollment in personalized immunotherapy for melanoma

Women’s health at heart of new Edinburgh pop-up festival

Guadalupe Sabio wins a Diario Médico’s Admirables Award

After a tumor disrupts an Illinois woman’s fertility, brain surgery helps her get pregnant

Journée mondiale sans tabac : les HUS engagés dans le soin et la prévention

Public dialogue explores solar radiation modification research

Mit Bakterien zu klimaneutralen Kunststoffen und Kosmetika

Making climate-neutral plastics and cosmetics using bacteria

From the Emergency Department to the Capitol: A doctor’s impact beyond the bedside

Survey shows little shift in Americans’ views on political violence

Il Policlinico di Milano vanta una delle biblioteche ospedaliere più importanti d’Europa

Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026

Comment diminuer le nombre de maladies cardiovasculaires ?

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Change in Siegfried’s management team

Cyclic deformation resets a rock’s microstructural clock

[IBENTO][IBENTO]Symposium for the 10 anniversary of the PMDA Hokuriku Branch

Sumitomo Pharma Announces Organizational Change, Change in the Responsibilities of Executive Officer, and Personnel Change

Flat Pack Packaging Now Uses Less Plastic with New Direct Printing Machine

[Editorial] The promise and perils of AI in oncology

[Correspondence] Para-aortic lymph nodes in oligometastatic pancreatic ductal adenocarcinoma – Authors' reply

[Correspondence] On the survival benefit from sentinel node biopsy for melanoma – Authors' reply

[Corrections] Correction to Lancet Oncol 2026; 27: e238–47

[Corrections] Correction to Lancet Oncol 2026; 27: 614–24

[Comment] [177Lu]Lu-dota-tate radioligand therapy for advanced pancreatic neuroendocrine tumours

[Correspondence] Para-aortic lymph nodes in oligometastatic pancreatic ductal adenocarcinoma

[Correspondence] On the survival benefit from sentinel node biopsy for melanoma

[Correspondence] Brachytherapy capacity gaps and cancer control priorities

当社名をかたるSNSなりすましアカウントに関する注意喚起

「健康経営優良法人2026（大規模法人部門）」に認定

S&P GlobalによるSustainability Yearbook Member 2026に選定

緑内障・高眼圧症治療剤「ロープレッサ®点眼液0.02%」国内における製造販売承認を取得

「ちびまる子ちゃん」と考える、子どもの近視 ― 日常の気づきから“まずは眼科へ”を伝える疾患啓発メッセージを全国に展開 ―

Santen中国、5つの緑内障点眼薬について、中国本土における独占的な流通および販売促進に関する契約を締結

後天性眼瞼下垂治療剤「アップニーク®ミニ点眼液0.1%」発売のお知らせ

役員人事に関するお知らせ

アフリベルセプト硝子体内注射用キット40 mg/mL「バイエル」の発売予定について

AAV8-mediated mouse/human PROC expression rescues thrombophilia in hereditary protein C-deficient mice

Efficient Bridge Monitoring

Accelerating the Production of Higher-Performance Batteries

Outcomes of DCD Versus DBD Heart Transplantation: Impact of Primary Graft Dysfunction Recovery Trajectory

2026年度「参天製薬 奨学寄付プログラム」の応募を開始いたしました

Efficacy, safety and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to Standard of Care First-Line Therapy: the Phase 2 TeLuRide-005 trial in Stage 4 Non-Small Cell Lung Cancer – Poster Presentation, ASCO 2026

Adaptive Phase 2/3 Study of EIK1001, a TLR7/8 Dual Agonist, in Combination with Pembrolizumab, as First-Line Therapy in Participants with Advanced Melanoma (TeLuRide-006) – Poster Presentation, ASCO 2026

A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008) – Poster Presentation, ASCO 2026

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

[Comment] From shortage to synergy: transforming global radiology workforce capacity with digital innovation and task-shifting

[Comment] Regionally anchored, globally connected: lessons from the Pacific on the cancer workforce crisis

[Comment] The global cancer workforce crisis: a shared responsibility, a united front

[Comment] Beyond the count: the unseen foundations of cancer care

[Comment] AI and the cancer workforce: what problem are we solving?

[Comment] The UK's radiotherapy workforce shortage: a case for reform

Taking cooking together to the next level: an inspiring story from Community Kids Narre Warren

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, Including Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors – Poster Presentation, ASCO 2026

EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a Phase 1/2 study EIK1003-001 in advanced solid tumors – Poster Presentation, ASCO 2026

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

2026年度「参天製薬奨学寄付プログラム」の応募を開始いたしました